- Home
- MREO vs SLRN Comparison
MREO vs SLRN Comparison
Compare MREO & SLRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MREO
- SLRN
- Stock Information
- Founded
- MREO 2015
- SLRN 2020
- Country
- MREO United Kingdom
- SLRN United States
- Employees
- MREO N/A
- SLRN N/A
- Industry
- MREO Biotechnology: Pharmaceutical Preparations
- SLRN Biotechnology: Pharmaceutical Preparations
- Sector
- MREO Health Care
- SLRN Health Care
- Exchange
- MREO Nasdaq
- SLRN Nasdaq
- Market Cap
- MREO 577.6M
- SLRN 485.6M
- IPO Year
- MREO N/A
- SLRN 2023
- Fundamental
- Price
- MREO $3.68
- SLRN $4.33
- Analyst Decision
- MREO Strong Buy
- SLRN Buy
- Analyst Count
- MREO 4
- SLRN 6
- Target Price
- MREO $7.50
- SLRN $11.50
- AVG Volume (30 Days)
- MREO 769.7K
- SLRN 476.2K
- Earning Date
- MREO 11-12-2024
- SLRN 11-13-2024
- Dividend Yield
- MREO N/A
- SLRN N/A
- EPS Growth
- MREO N/A
- SLRN N/A
- EPS
- MREO N/A
- SLRN N/A
- Revenue
- MREO $1,000,000.00
- SLRN N/A
- Revenue This Year
- MREO $16.39
- SLRN N/A
- Revenue Next Year
- MREO $9.44
- SLRN N/A
- P/E Ratio
- MREO N/A
- SLRN N/A
- Revenue Growth
- MREO N/A
- SLRN N/A
- 52 Week Low
- MREO $1.86
- SLRN $3.36
- 52 Week High
- MREO $5.02
- SLRN $8.89
- Technical
- Relative Strength Index (RSI)
- MREO 39.84
- SLRN 30.07
- Support Level
- MREO $3.18
- SLRN $4.29
- Resistance Level
- MREO $4.40
- SLRN $4.84
- Average True Range (ATR)
- MREO 0.24
- SLRN 0.44
- MACD
- MREO -0.06
- SLRN -0.21
- Stochastic Oscillator
- MREO 41.39
- SLRN 3.15
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
About SLRN ACELYRIN INC.
Acelyrin Inc is a late-stage clinical biopharmaceutical company. It is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of of transformative medicines.